Liver Disease Treatment Market

Liver Disease Treatment Market Size (2024 to 2029)

The global liver disease treatment market size is predicted to be worth USD 28.02 billion by 2029 from USD 16.10 billion in 2024, growing at a CAGR of 11.72% during the forecast period.

Current Scenario of the Global Liver Disease Treatment Market

The liver is a vital organ of the body performing umpteen complex functions such as fighting infections, removing toxins, and bile secretion. It produces clotting factors, proteins, and cholesterol, among others. Malfunctioning of the liver can be life-threatening. It can cause multiple acute and chronic diseases (hepatitis, non-alcoholic fatty liver disease, liver cancer, liver tumor, and liver cirrhosis). The initial liver damage symptoms include nausea, fatigue, diarrhea, jaundice, swollen abdomen, and mental disorientation. Acute liver damage can be treated through proper medication if detected early. Otherwise, a liver transplant is required. Liver damage can be prevented by adopting a healthy lifestyle and practicing proper hygiene. 

MARKET DRIVERS

The growing patient population suffering from liver diseases is one of the key factors propelling the liver disease treatment market growth. 

The incidence and prevalence of liver diseases are on the rise. The number of people suffering from liver diseases has increased significantly in recent years due to viral infections, alcohol abuse, obesity and lifestyle changes. As per the data published by the World Health Organization (WHO), an estimated 2 million people worldwide dies from liver diseases each year and liver diseases are the 11th leading cause of death globally. As per the same source, an estimated 257 million people with hepatitis B and 71 million people with hepatitis C lived in 2019. WHO says alcohol consumption is anticipated to cause 20% to 50% of liver cirrhosis. The growing obese population has also increased the risk of non-alcoholic fatty liver disease caused by the build-up of fat in the liver. The obese population has doubled since 1980. In 2014, approximately 13% of the world’s population, more than 600 million adults, were obese. However, the awareness among people and healthcare professionals regarding liver diseases has been growing constantly and resulting in the increasing adoption of early diagnosis, screening and timely treatment of liver diseases.

Technological advancements in liver disease diagnosis that include imaging techniques, liver function tests and biomarker-based diagnostics further promote the market growth. These technological advancements have improved the early detection and accurate assessment of liver diseases. The development of new therapeutic options such as antiviral drugs, immunosuppressants, targeted therapies and liver transplantation techniques that can provide more effective and diverse treatment choices for liver diseases fuels the market growth.

The growing R&D efforts to develop novel treatment approaches and therapeutic targets for liver diseases, an increasing number of initiatives and funding to address liver diseases including prevention, diagnosis and treatment, the rising awareness about liver diseases, the importance of early diagnosis, the healthcare expenditure and improved access to healthcare services in many regions boost the growth rate of the liver disease treatment market. The growing aging population, rising awareness, improving healthcare infrastructure, and rising disposable income in emerging markets and rising number of advancements in surgical techniques, minimally invasive procedures and interventional radiology further support the market growth.

MARKET RESTRAINTS

High costs of the medications, procedures and surgeries associated with liver disease treatment majorly hamper the market growth.

Inadequate healthcare infrastructure, especially in rural or underserved areas, poor awareness among the general population and healthcare professionals about liver diseases and their symptoms and stigma associated with certain liver diseases, such as viral hepatitis or alcohol-related liver diseases hinder the market growth. The complexity of liver transplantation, stringent regulations and limited research and development pipeline for liver disease treatments inhibit the market’s growth rate.

REPORT COVERAGE

SEGMENTAL ANALYSIS

 Liver Disease Treatment Market  By Treatment Modality

Based on the treatment modality, the antiviral segment accounted for the largest share of the liver disease treatment market in 2022 and the domination of the segment is anticipated to continue during the forecast period. The growing prevalence of viral hepatitis infections, increasing number of advancements in antiviral therapies, rising awareness and screening programs for hepatitis B and C and growing emphasis on achieving viral suppression and preventing disease progression primarily drive the segmental growth.

The vaccines segment had a considerable share of the global market in 2022 and is expected to grow at a notable share of the global market during the forecast period. The growing emphasis on preventive healthcare, increasing number of government immunization programs, rising vaccination efforts for hepatitis B and increasing awareness of the importance of vaccination against hepatitis viruses majorly propel the segmental growth.

The chemotherapy segment is predicted to witness a healthy CAGR during the forecast period owing to the growing incidence of liver cancer, an increasing number of advancements in chemotherapy regimens, rising emphasis on personalized medicine and targeted therapies and improvements in combination therapies.

Liver Disease Treatment Market  By Disease Type

Based on the disease type, the liver cancer segment is anticipated to account for the largest share of the global market during the forecast period. The growing prevalence of liver cancer is one of the key factors propelling segmental growth. The growing prevalence of risk factors like viral hepatitis, alcohol abuse, and non-alcoholic fatty liver disease, the increasing number of advances in early detection and diagnosis of liver cancer and rising treatment options, including surgery, chemotherapy, targeted therapies, and immunotherapy further boost the growth rate of the segment.

The hepatitis segment is predicted to capture a substantial share of the global market during the forecast period owing to the growing prevalence of viral hepatitis infections (hepatitis B and C), growing awareness and screening programs. The growing number of advancements in antiviral therapies and rising emphasis on early diagnosis and treatment further contribute to segmental growth.

The Non-alcoholic fatty liver disease (NAFLD) segment is anticipated to hold a considerable share of the worldwide market during the forecast period. Factors such as the growing incidence of obesity and metabolic syndrome, rising prevalence of NAFLD as a consequence of lifestyle changes, increasing awareness and diagnosis of NAFLD and growing focus on lifestyle modifications and pharmacological interventions drive the segmental growth.

 REGIONAL ANALYSIS

Geographically, the North American liver disease treatment market had the largest share of the global market in 2022 and is estimated to dominate the global market during the forecast period. The growth of the North American market is majorly driven by the growing patient population of liver diseases such as hepatitis and high healthcare expenditure. The presence of well-developed healthcare infrastructure, favorable reimbursement policies for liver disease treatment, rapid adoption of advanced therapies and technologies, strong research and development activities in liver disease treatment and increasing emphasis on early diagnosis and intervention further propel the growth of the North American market. The U.S. accounted for the major share of the North American market in 2022 and is expected to grow at a promising CAGR during the forecast period owing to the growing prevalence of liver diseases, the growing aging population and increasing awareness regarding the available treatment options for liver diseases among the U.S. population. The number of adults diagnosed with liver disease in the U.S is 4.5 million, and the mortality rate is 44,358. Canada is expected to account for a considerable share of the North American market during the forecast period. As per the estimation, 1 in 10 Canadians, or more than 3 million have liver disease.

The European liver disease treatment market had the second largest share of the global market in 2022 and is expected to grow at a lucrative CAGR during the forecast period owing to the growing patient population of liver diseases. Liver disease in Europe is a critical issue with growing cases of Cirrhosis and liver. An estimated 5 million are carriers of hepatitis C in Western Europe. According to the WHO, liver cancer is responsible for approximately 47,000 deaths yearly in the EU. The presence of established liver disease treatment guidelines and healthcare systems, increasing emphasis on preventive measures, vaccination and early detection and rapid adoption of advanced treatment modalities and technologies contribute to the growth rate of the European market. The growing awareness and support for liver disease research and clinical trials and growing healthcare expenditure on liver disease management further boost the growth rate of the European market. Germany, UK, and France account for the region's highest share in liver disease treatment in Europe. Germany led the market in Europe and is expected to grow at a healthy CAGR during the forecast period due to factors such as increasing reimbursement policies for liver diseases. The government and other organizations are bringing awareness to the public by conducting liver disease programs.

The Asia-Pacific liver cancer treatment market is expected to have rapid growth and register the fastest CAGR in the global market during the forecast period. The presence of a large population base and high prevalence of viral hepatitis, NAFLD and liver cancer majorly contribute to the APAC market growth. The growing healthcare spending, improving healthcare infrastructure, rising awareness and government initiatives for liver disease prevention and treatment, rapid adoption of vaccination programs and screening campaigns, development of innovative treatment approaches and therapies and expansion of pharmaceutical companies and clinical research activities further fuel the growth rate of the APAC market. As per the data published by World Hepatitis Alliance, an estimated 60% of global hepatitis B cases are originating from Asia. China, India and Japan are predicted to account for the major share of the APAC market during the forecast period.

Latin America had a considerable share of the global market in 2022 and is expected to grow at a healthy CAGR during the forecast period. The growing aging population and the rising incidence of liver diseases in the Latin American region primarily drive the Latin American liver disease treatment market growth. The growing emphasis on liver disease prevention and control programs, increasing access to healthcare services and diagnostics, rising investments to improve the healthcare infrastructure and facilities, a growing number of public-private partnerships for liver disease management and the development of novel therapies and treatment options further promote the growth of the Latin American market. Brazil is projected to hold the leading share of the Latin American market during the forecast period. Advanced Biological Laboratories agreed with the LALREAN (Latin America Liver Research Awareness and Educational Network) to study liver diseases representing an active cohort of over 7,000HCV infected patients comprising 18 treatment centers. The frequent change of obesity-related metabolic syndrome results in a high frequency of non-alcoholic fatty liver disease driving the Brazilian market growth.

The MEA liver disease treatment market captured a moderate share of the global market in 2022 and is estimated to grow at a steady CAGR during the forecast period. The growing patient population suffering from liver cirrhosis, the growing public awareness and high-level government commitments favor the MEA market growth. The MEA is projected to have significant growth opportunities because of rapidly developing healthcare amenities among Saudi Arabia, Oman, and Qatar. Over 200,000 deaths occurred in Sub-Saharan Africa due to liver diseases resulting in liver cirrhosis and hepatocellular carcinoma. Over 80% of Africa's liver disease burden is due to endemic blood-borne virus infections like HIV, hepatitis B, and hepatitis C.

KEY PLAYERS IN THE LIVER DISEASE TREATMENT MARKET

Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany) and AstraZeneca (United Kingdom) are some of the major players in the global liver disease treatment market.

DETAILED SEGMENTATION OF THE GLOBAL LIVER DISEASE TREATMENT MARKET INCLUDED IN THIS REPORT

This research report on the global liver disease treatment market has been segmented and sub-segmented based on the treatment modality, disease type, and region.

By Treatment Modality

• Antiviral
• Vaccines
• Chemotherapy
• Immunosuppressive Agents
• Corticosteroids

By Disease Type

• Hepatitis
• Non-Alcoholic Fatty Liver Disease
• Alcohol-Induced
• Liver Cancer

By Region

• North America
• Europe
• APAC
• Latin America
• The Middle East and Africa